hope not because i sold my great biotech and metaverse plays today. only had a small amount of MTTR and sold premarket hoping to buy back in on the cheap--didn't dip quite low enough for me to buy though. Xair I took profits again on today's spike. will buy back in if the FDA decision continues to be delayed: Beyond Air Inc NASDAQ: XAIR 15.61 USD +1.73 (12.46%)today Closed: Nov 26, 3:39 PM EST • Disclaimer After hours 15.65 +0.040 (0.26%)
Stoney!!!!!! WHICH ONE OF THOSE IMAGES IS...... THE SEER?! Going through my GBA mailbag and listening to the myriad of loyal readers that got in when I said to.... and out when I said to....... I am at a loss for words. A humble tear streams down VZ's cheek. Hit after hit after hit..... and then.... MOST IMPORTANTLY.... ....more winners offered up daily! Not 30 ideas, not whims of fancy originating from other websites, , but well researched, ORIGINAL quality picks How do I do it? No idea! Seer! All I can say is thank you Stoney for allowing me to share this thread, and albeit I climb out on that perpetually thin limb of stock advice that so many before me have fallen from on their way to obscurity, but for the moment at least, I can strut with pride as for at least here and ALL of the GBA's threads from 4 years ago and counting ..... The GREATEST STOCK PICKER GBA HAS EVER SEEN. NO ONE IS EVEN CLOSE edit: All that and humble pie too.
For the uninformed, pardon my braggadociosness. It's all bs lol.... Merely a response to this: Gotta keep Stoney in line.
Yeah but it's a money-maker too. For real. I am pissed about my Zoom call though. I was dead ass wrong.
Yup lots of talk of XAIR around the Thanksgiving table- people are surprised it has held up so well. I am not because there has been no sell the news announcement yet. It has been a Great stock. Another $5---> $15 winner from GBA! As I remember I got out at $13.50 have to double check on that. Way to go janes! I have not one but two dead cars/jeeps in the driveway. Ct is murder. We don't have a garage. I saw an image of ' Black Friday ' rush at a mall up here and it was so sad about seven guys huffing vapes just strolled in-- there is no crowds that I see. Shopping is almost entirely online now.
Galidesivir This nucleoside RNA polymerase inhibitor disrupts the viral replication process and has the potential to fight multiple viral threats Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika. Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials by both intravenous and intramuscular routes of administration in healthy subjects. In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. Galidesivir has also demonstrated broad-spectrum activity in vitro against more than 20 ribonucleic acid (RNA) viruses in nine different families, including coronaviruses, filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses and flaviviruses. BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions. In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. Galidesivir is an adenosine nucleoside analog that acts to block viral RNA polymerase. RNA polymerase plays a crucial role in the viral replication process, including transcription and replication of the virus genome. Nucleoside RNA polymerase inhibitors, such as galidesivir, are metabolized to the active triphosphate (nucleotide) form by cellular kinases. The drug nucleotide binds to the viral enzyme active site and becomes incorporated into the growing viral RNA strand, leading to premature chain termination. Interfering with the replication process is a well-established antiviral strategy that has been successfully exploited in developing such life-saving drugs as the nucleoside inhibitors of HIV and acyclovir for herpes simplex complex. This approach could allow a single broad-spectrum drug like galidesivir to address gaps in the U.S. government’s medical countermeasure plan and to possibly replace multiple, pathogen-specific drugs for use in response to both natural outbreaks and bioterrorist threats. Galidesivir is investigational and has not been deemed safe and effective by the FDA
That above anti viral is BCRX. I have done considerable work and find almost all Vaccines that I can tell target the Spike Protein. Here are 2 bios of interest trying something different-) Several companies, including the California-based Gritstone Bio, have decided to take a more targeted tack, selecting a subset of coronavirus traits to package into some of their repertoire of inoculations. One of Gritstone’s vaccines, which is currently in human trials, contains not only spike but also chunks of two proteins that the coronavirus keeps in its interior: one called nucleocapsid, which helps the pathogen package its genetic material, and another called ORF3a, which helps newly formed coronavirus particles mosey out of cells. T cells are already an essential part of the immune response our bodies mount to our current vaccines, because they react very strongly to spike. But Andrew Allen, Gritstone’s CEO, told me that the T cells in our bodies could be doingmore,if given the chance. T cells in people who have been infected by the coronavirus can home in on many parts of the virust hat aren’t packaged into most vaccines. Some of these immune targets, encouragingly, have mutated more slowly than spike, raising hopes of protection that’s both potent and long-lived. Early studies suggest that new coronavirus variants that bamboozle certain antibodies are still nowhere near stumping the body’s diverse cavalry of T cells. A) Gritstone bio, Inc. (GRTS) NasdaqGS - Nasdaq 11.12+0.28 (+2.58%) At close: November 26 1:00PM EST 11.30+0.18 (+1.62%) After hours:Nov 26, 04:55PM EST Another company, California-based Immunity Bio, plans to push the pro-T-cell paradigm even further. It has several versions of a spike-nucleocapsid combo vaccine in clinical trials, some of which are being delivered as drops into the mouth, and will soon be testing out an intranasal spray. Patrick Soon-Shiong, the company’s CEO, told me that this route of administration is a much better pantomime of how the coronavirus actually enters the human body—through the airway, where it will encourage the production of unique populations of antibodies and T cells tailor-made to guard these tissues. Many of those T cells will even hunker down in and around the lungs, where they can head off the virus immediately, something that doesn’t happen as efficiently when we inject vaccines into our deltoids. “I think local immunity is going to be what we need, if we’re thinking ahead,” Donna Farber, an immunologist at Columbia University, told me. Some next-generation vaccines could operate as solo acts for the un-immunized; others could be boosters for people whose defenses against the coronavirus are no longer up to snuff. B) ImmunityBio, Inc. (IBRX) NasdaqGS - NasdaqW 6.50+0.15 (+2.36%) At close: November 26 1:00PM EST 6.55+0.05 (+0.77%) After hours:Nov 26, 04:56PM EST Amyris takes bite out of sharks with Covid vaccine joint venture- Nov 8, 2021, 5:14pm EST The East Bay company's synthetic biology work, coupled with RNA technology it has licensed, could help Patrick Soon-Shiong's ImmunityBio produce a Covid vaccine.